This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Nov;15(11):1582-4.

doi: 10.1093/annonc/mdh445.

Chemotherapy for patients with hormone-refractory prostate cancer

F Joly, I F Tannock

PMID: 15520057
DOI: 10.1093/annonc/mdh445

Free article

Editorial

Chemotherapy for patients with hormone-refractory prostate cancer

F Joly et al. Ann Oncol. 2004 Nov.

Free article

. 2004 Nov;15(11):1582-4.

doi: 10.1093/annonc/mdh445.

Authors

F Joly, I F Tannock

PMID: 15520057
DOI: 10.1093/annonc/mdh445

No abstract available

PubMed Disclaimer

Comment on

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, Oudard S. Abratt RP, et al. Ann Oncol. 2004 Nov;15(11):1613-21. doi: 10.1093/annonc/mdh429. Ann Oncol. 2004. PMID: 15520061 Clinical Trial.

Similar articles

Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ, Guerra ML, Kronish L. Koletsky AJ, et al. Cancer J. 2003 Jul-Aug;9(4):286-92. doi: 10.1097/00130404-200307000-00011. Cancer J. 2003. PMID: 12967139 Clinical Trial.
A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S, Engle E, Jin L, Todd M, DiPaola RS. Goodin S, et al. Cancer Chemother Pharmacol. 2005 Aug;56(2):199-204. doi: 10.1007/s00280-004-0980-1. Epub 2005 Apr 19. Cancer Chemother Pharmacol. 2005. PMID: 15838657 Clinical Trial.
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Belani CP; TAX 326 Study Group. Belani CP, et al. Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. doi: 10.1053/sonc.2002.34255. Semin Oncol. 2002. PMID: 12170445 Review.
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hahn NM, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6094-9. doi: 10.1158/1078-0432.CCR-06-1188. Clin Cancer Res. 2006. PMID: 17062685 Clinical Trial.
[Chemotherapy for prostate cancer].
Itoh N. Itoh N. Nihon Rinsho. 2005 Feb;63(2):293-7. Nihon Rinsho. 2005. PMID: 15714981 Review. Japanese.

See all similar articles

Cited by

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells.
Montagnani Marelli M, Beretta G, Moretti RM. Montagnani Marelli M, et al. Int J Mol Sci. 2023 Mar 3;24(5):4923. doi: 10.3390/ijms24054923. Int J Mol Sci. 2023. PMID: 36902362 Free PMC article.
Current treatment strategies for castration-resistant prostate cancer.
Kim SJ, Kim SI. Kim SJ, et al. Korean J Urol. 2011 Mar;52(3):157-65. doi: 10.4111/kju.2011.52.3.157. Epub 2011 Mar 18. Korean J Urol. 2011. PMID: 21461278 Free PMC article.
New multidisciplinary prostate bone metastases clinic: first of its kind in Canada.
Goh P, Harris K, Napolskikh J, Chow E, Sinclair E, Emmenegger U, Lemon S, Yee A, Wynnychuk L, Myers J, Danjoux C, Ko Y; Bone Metastases Site Group. Goh P, et al. Curr Oncol. 2007 Feb;14(1):9-12. doi: 10.3747/co.2007.101. Curr Oncol. 2007. PMID: 17576458 Free PMC article.
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Bhardwaj A, Singh S, Srivastava SK, Arora S, Hyde SJ, Andrews J, Grizzle WE, Singh AP. Bhardwaj A, et al. Br J Cancer. 2014 Apr 15;110(8):2000-10. doi: 10.1038/bjc.2014.141. Epub 2014 Mar 18. Br J Cancer. 2014. PMID: 24642616 Free PMC article.
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Bhardwaj A, et al. Mol Cancer Ther. 2011 May;10(5):720-31. doi: 10.1158/1535-7163.MCT-10-1096. Epub 2011 Mar 10. Mol Cancer Ther. 2011. PMID: 21393425 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information